PRCT Share Price Performance
US$24.22
-33.37 (-57.94%)
52.3% undervalued intrinsic discount
US$50.73
Fair Value
Price US$24.22
AnalystConsensusTarget US$50.73
AnalystHighTarget US$62.00
AnalystLowTarget US$38.00
Fair ValueUS$32.50
Share Pricen/a
PROCEPT BioRobotics Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 38 Fair Values set on narratives written by author
PRCT Community Narratives
AN
Fair Value US$32.5 25.5% undervalued intrinsic discount
PRCT: Share Price Will Likely React Sharply To Upcoming Earnings Data
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
Fair Value US$62 60.9% undervalued intrinsic discount
Aging Population And Robotic Advances Will Unlock Urologic Potential
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$38 36.3% undervalued intrinsic discount
Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
PRCT: Share Price Will Likely React Sharply To Upcoming Earnings Data
Key Takeaways Expanded reimbursement and increased adoption promise accelerated revenue growth and margin expansion, as Aquablation becomes a standard for minimally invasive therapy in more hospitals. International growth, successful clinical trials, and new approvals are unlocking additional long-term revenue streams and expanding market reach for sustained profitability.Read more
373
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
US$32.5
25.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
13.36%
Future PE
30.42x
Price in 2029
US$40.25
Aging Population And Robotic Advances Will Unlock Urologic Potential
Key Takeaways Accelerated adoption, streamlined reimbursement, and demographic trends are expected to drive stronger-than-expected revenue growth, operating leverage, and recurring handpiece demand. Expansion into new procedure categories and global markets, backed by clinical trials, strong cash reserves, and experienced leadership, positions the company for substantial long-term upside.Read more
53
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$62
60.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
1.19%
Future PE
575.15x
Price in 2029
US$76.87
Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress
Key Takeaways Growth potential driven by demographic trends and innovation faces threats from competition, pricing pressure, and possible market shifts to non-device treatments. Expansion and recurring revenue are promising, but high costs, reimbursement risks, and geopolitical factors could constrain margins and profitability.Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$38
36.3% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
12.9%
Future PE
35.9x
Price in 2029
US$47.42
Trending Discussion
Recently Updated Narratives
AN
PRCT: Long Term Margin Targets And Guidance Reset Will Support Rebound
Fair Value: US$32.5 25.5% undervalued intrinsic discount
24 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PRCT: Higher Modeled Margins And Investor Day Focus Will Support Rebound Potential
Fair Value: US$62 60.9% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PRCT: Earnings Volatility Setup Will Likely Drive Future Share Repricing
Fair Value: US$38 36.3% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
PROCEPT BioRobotics Corporation Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.69
- 63.70%
- -31.02%
- 14.1%
About PRCT
- Founded
- 2007
- Employees
- 888
- CEO
- WebsiteView website
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
